CYCLOSPORIN-CONTAINING PHARMACEUTICAL COMPOSITIONS

Patent number: AU607506B Publication date: 1991-03-07

Inventor: KURIHARA KOZO; MURANO MASARU

Applicant: SANKYO CO

Classification:

-international: A61K47/40; A61K47/40; (IPC1-7): A61K47/40;

A61K37/02 - european:

Application number: AU19880017386 19880603 Priority number(s): JP19870140730A 19870604

Report a data error here

Abstract not available for AU607506B

Data supplied from the esp@cenet database - Worldwide

607506 status

PAEN02BC V3.82 PATENT ADMINISTRATION SYSTEM 14/03/06 11:18:15 Page 1

Convention application

Application Id : 17386 / 88 Serial Number: 607506

03/06/88

JAPAN

18

215

Relevant Act Patents Act 1990(Transitional) Date Application Keyed 15/06/88

Status : Patent Sealed

Application Type Filing Date

Country of origin Number of pages Number of CDROMS

CDROM Presence Filing fee

Earliest Priority Date

04/06/87

Australian OPI Date

Complete Filing Date

22/12/88

21/06/90

54

03/06/88

Patentee Name Novartis AG

Address : Lichtstrasse 35. CH-4002 Basel. Switzerland

Inventor Name Kozo Kurihara Masaru Murano

Invention Title

Cyclosporin-containing pharmaceutical compositions

Full Title Cyclosporin-containing pharmaceutical compositions

ATTORNEY ADDRESS

Griffith Hack GPO Box 4164 SYDNEY NSW 2001

EXAMINATION DETAILS Direction Date

Request Type Reduest Fee Paid

Deferment Date Examiner J HANSON Date Sent to Exam

Search Results Requested Abstract Requested

Re-exam request date International (Type) Search Results

ACCEPTANCE DETAILS Date Accepted

11/12/90 Date FE Printed 08/02/91 Acceptance Type After full exam.

Applicant Ref 13093-BT:AMP/LT Amend to Spec 2,3 Amend to Apln 1

Amend to Drwg Final date for Acceptance 21/03/92

PAFN02BD V3.65

PATENT ADMINISTRATION SYSTEM

20/07/89

10/12/90

260

14/03/06 11:18:16 Page 2

Request Lodgement date 18/09/89

Acceptance Advert Date 07/03/91

Acceptance Postponed

First Report Date

Abstract Received

Opposition Date Opposition Result

Examination Section

Further Report Date

Search Results Received

Page 1

Full examination following direction

607506 status

Application Id: 17386 / 88 Serial Number : 607506

Date Sealed 23/07/91 Sealed Advertised Date 08/08/91 Accept Not Sealed Advert

Lapsed Advertised Date Lapsed Type Withdrawn Advertised Date Withdrawn Type Refused Advertised Date

Ceased/Expired Advert

CHANGE OF PATENTEE DETAILS:

Assignment under S 187, Reg 19.1 : RECORD 1

Date of Request 31/01/01

Date of Registration 07/02/01 Instrument Date(s): 03/08/99 Date Parties Notified 12/02/01 Deed of Assignment

Instrument Details:

Enclosures Deed of Assignment Interest Full! Scope Australia

Service Address Davies Collison Cave Level 15 1 Nicholson Street MELBOURNE VTC 3000

Old Name and Address: Sankvo Company Limited 5-1 Nihonbashi Honcho 3-chome Chuo-ku Tokyo Japan

New Name and Address: Novartis AG Lichtstrasse 35, CH-4002 Basel, Switzerland

FEE HISTORY

Paid Date Paid to Date Fee Paid Payor Code Reference 03/06/90 INTITAL PERIOD

03/06/91 30/05/90 75 CP 23/04/91 03/06/92 100 CP 18/05/92 03/06/93 135 CP 17/05/93 03/06/94 165 CP 16/05/94 03/06/95 200 CP 03/06/96 16/05/95 CP 13/05/96 03/06/97 270 CP 12/05/97 03/06/98 305 CJ 18/05/98 03/06/99 345 ĊĴ 17/05/99 03/06/00 385 CJ 15/05/00 03/06/01 430 CJ 24/05/01 03/06/02 475 CJ 03/06/03 29/04/02 525 NV 14/05/03 03/06/04 650 NV 12/05/04 03/06/05 700 NV 10/05/05 03/06/06 800 ΝV

PAENO2BE V3.51 PATENT ADMINISTRATION SYSTEM 14/03/06 11:18:16 Page 3

Serial Number: 607506 Application Id: 17386 / 88

607506 status

Last Agency Address NOVARTIS AG Patent and Trademark Dept Klybeckstrasse 141 CH-4002 Basel SWITZERLAND

PRIORITY DETAILS
Application

Date Number 04/06/87 62-140730 Country JAPAN

First

********* End of Application *********

IPC Mark A61K 47/40 (2006.01) A61K 37/02 (1985.01)

Υ

© 1989 DERWENT PUBLICATIONS LTD.

	00/000/14 00
805 SANY 04.04.87 SANYO K.	
Oc.06.87.JP-140730 (22.12.88) Aolt-37/02 Aolt-47 Compan. contp. cyclosporin and alpha-cyclodextrin - useful for	NON NO
ppressing the interval tyriem, topical measurement of compagning filehout's syndrome etc.	
Pharmaceutical conpen. comprises at least one symbosporin (1)	12
together with an rait, of e-cyclodextein (aCD) or functional darly, sufficient to solubilise (f) in water.	
USE To suppressing the inmune system, for topical treatment of the coular symptoms of Behout's Syndrome, for treatment	11-12800. The compan, it pref. in the form of an aq soln, with a set compan, of aCD 10-128, eagp, 20-130 mg/ml and a comen of control of a for the compan of the company of the form of th
of herpetic keratitis and spring estarrh, and during kerato- pleaty (I) also have antifungal and antiphiogetic activities.	-
ADVANTAGE. The water-soluble complex shows reduced tendency for	
(1) to appeade out on contact with water in tyrops. W. introduce forms, and gives high bloavallability by oral admin. The complex one formulated into eq. compans. Allowing reduced counter irritation and evertants aide effects on topical admin.	(1) to suppose out on control with when in proper, utilized posder which was completely wishing in series forms, and gives high blowaliability by out sloths. The security is populated by your statement of complex, and gives high blowaliability by out sloths. The security is the visit of the security o
to the sye.	AU3817386-A